Analyst Research

Report Title Price
Provider: GlobalData
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime
Provider: Sadif Analytics Prime

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biomerieux SA Receives FDA Approval for THxIDTM-BRAF Companion Diagnostic Test

Thursday, 30 May 2013 02:35am EDT 

Biomerieux SA announced that its molecular test THxIDTM-BRAF received Pre Market Approval from the FDA (Food and Drug Administration) for commercialization in the United States. This test is intended for the qualitative and simultaneous detection of both BRAF V600E and V600K mutations in late stage metastatic melanoma tumor samples. 

Company Quote

0.42 +0.50%
4:18am EST